HUMALOG MIX 75/25 Drug Profile

Summary for Tradename: HUMALOG MIX 75/25

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for HUMALOG MIX 75/25

Recent Clinical Trials for HUMALOG MIX 75/25

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Stanford University	PHASE1
Xentria, Inc.	PHASE1
Steno Diabetes Center Copenhagen	NA

See all HUMALOG MIX 75/25 clinical trials

Pharmacology for HUMALOG MIX 75/25

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMALOG MIX 75/25 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMALOG MIX 75/25 Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HUMALOG MIX 75/25 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMALOG MIX 75/25	insulin lispro protamine and insulin lispro	Injectable Suspension	021017	10,660,941	2037-02-17	Patent claims search

Market Dynamics and Financial Trajectory for HUMALOG MIX 75/25

Last updated: February 20, 2026

HUMALOG MIX 75/25 is a pre-mixed insulin analog produced by Eli Lilly, combining 75% insulin lispro and 25% insulin lispro protamine. It targets adult patients with type 2 diabetes requiring basal-bred insulin therapy.

Market Overview

Market Size and Growth

The global insulin market reached $50 billion in 2022, influenced by increasing diabetes prevalence, with a compound annual growth rate (CAGR) of 7% projected through 2027[1].

Pre-mixed insulins account for 35% of all insulin sales, driven by ease of administration and cost considerations[2].

Competitive Landscape

Key competitors include Novo Nordisk's Ryzodeg 70/30, Sanofi's Mix insulin products, and Biosimilar offerings:

• Ryzodeg 70/30: Launched in 2013, includes insulin degludec and insulin aspart.
• Sanofi Mixes: Historically dominate in multiple markets with Humalog Mix 75/25's primary rival.
• Biosimilars: Emerging biosimilars aim to reduce costs but face regulatory and patent hurdles.

Regulatory Status

In the U.S., HUMALOG MIX 75/25 has FDA approval since 2000, with ongoing patent protections until 2028[3]. Several international markets have approved the drug, with some regional variants.

Market Dynamics

Pricing and Reimbursement

HUMALOG MIX 75/25's average wholesale price (AWP) in the U.S. is approximately $150 per 10 mL vial. Reimbursement varies by insurer, with Medicaid and Medicare providing coverage that mitigates patient out-of-pocket costs.

Price competition increased as biosimilar insulins entered the market, pressuring prices for originator products.

Prescriber and Patient Adoption

Physicians favor premixed insulins for convenience and predictable glycemic control in suitable patients. However, there has been a shift toward basal-bolus regimens as more biosimilars and insulin analogs become available.

Patient adherence remains high among those using pre-mixed insulins due to ease of use.

Distribution and Access

Distribution channels are primarily managed through pharmacy networks, hospitals, and clinics. Access is impacted by insurance formularies, regional pricing policies, and supply chain dynamics.

Financial Trajectory

Revenue Projections

Eli Lilly reported approximately $2 billion in sales of HUMALOG products in 2022, with HUMALOG MIX 75/25 accounting for about 40% of these sales (~$800 million)[4].

Projected growth assumes:

• A compound annual increase of 4-6% in global insulin sales.
• Market share stabilization or slight decline due to biosimilar entry.
• Continued utilization in type 2 diabetes patients preferring premixed options.

Impact of Biosimilar Entry

Biosimilar insulins could erode 10-20% of sales over five years, especially in cost-sensitive markets. Price reductions of up to 30% are expected in competitive scenarios.

R&D and Patent Expiry

Patent expiration in 2028 may open pathways for biosimilars, affecting market share and pricing strategies.

Key Market Risks and Opportunities

Risks

• Patent expiration leading to biosimilar competition.
• Regulatory changes impacting reimbursement.
• Market preference shifting toward basal-bolus regimens.

Opportunities

• Expansion into emerging markets with rising diabetes prevalence.
• Development of next-generation biosimilars and fixed-dose combinations.
• Focused marketing toward physicians prescribing premixed insulins.

Strategic Recommendations

• Monitor biosimilar developments closely.
• Strengthen formulary placements to maintain market share.
• Innovate with combination products to differentiate offerings.
• Explore partnerships to expand access in emerging markets.

Key Takeaways

HUMALOG MIX 75/25 operates in a growing insulin market with stable demand in certain segments. Patent expiry in 2028 poses a significant risk, but product differentiation and market expansion could sustain revenue streams. Competitive pressure from biosimilars is mounting, leading to potential price reductions and volume shifts.

---

FAQs

1. When does the patent for HUMALOG MIX 75/25 expire?
The patent protection is scheduled to expire in 2028, opening the market to biosimilar competition.

2. How does HUMALOG MIX 75/25 compare in price to biosimilar insulins?
The originator’s vial pricing is around $150 per 10 mL, while biosimilars are expected to be priced 20-30% lower.

3. What is the primary patient demographic for HUMALOG MIX 75/25?
Adults with type 2 diabetes requiring premixed insulin therapy, especially those seeking convenience.

4. How is reimbursement structured globally?
Reimbursement varies, with developed markets like the U.S. covering through Medicaid and Medicare, often limiting patient out-of-pocket cost; emerging markets rely more on government programs and private insurers.

5. What are growth prospects beyond the next five years?
Market expansion in emerging economies, innovation in combination formulations, and biosimilar proliferation could influence long-term revenue.

---

Sources

[1] International Diabetes Federation. (2022). Diabetes Atlas.
[2] MarketWatch. (2022). Insulin Market Analysis.
[3] FDA. (2000). Approval of HUMALOG MIX 75/25.
[4] Eli Lilly Annual Report. (2022).